STEP-TEENS
The Phase 3 trials that won approval, and the outcome studies that came afterward on cardiovascular, kidney and sleep-apnea endpoints.
What is STEP-TEENS?
Semaglutide 2.4 mg in adolescents aged 12–17 with obesity (Weghuber et al., NEJM 2022).
Mean weight reduction 16.7% against 0.6% on placebo. ⚠ Pediatric trials do not measure facial appearance, so anyone citing this trial alongside “Ozempic face” claims is welding two unrelated things together.
GLP Watchdog writes these definitions from FDA labels and peer-reviewed PubMed literature.
Where STEP-TEENS comes up on this site
On GLP Watchdog, STEP-TEENS comes up in 1 tool.
Tools that use it
Connected terms
Other terms under Major trials
Where the evidence lives
- The full GLP-1 glossary (149 terms, 8 categories)
- Research articles — written from primary sources
- Tools and calculators
- Compare GLP-1 telehealth providers